Table 1 Demographics and clinical characteristics of patients treated with ONC201 who were evaluable for safety and efficacy

From: Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

	Patients (N = 20)
ONC201 (mg)	375	625
No. of Patients (%)	3 (15%)	17 (85%)
Male	2	8
Female	1	9
ECOG
ECOG = 0	2 (10%)	6 (30%)
ECOG = 1	1 (5%)	11 (55%)
Age (years)^a	80 (42–92)	64 (35–79)
Weight (kg)^a	51.3 (50.4–55.0)	82.7 (56.4–109.1)
Doses^a	21 (18–30)	19.6 (4–70)
Prior Therapies
Prior hormonal therapies^a	0	1.2 (1–6)
Prior chemotherapies^a	2.3 (0–4)	2.2 (0–7)
Prior immunotherapies^a	1 (0–2)	0.2 (0–1)
Prior targeted therapies^a	0.7 (0–2)	0.8 (0–4)
Prior Radiation^a	1.5 (1–2)	1 (1–3)
Prior Surgery^a	2 (2–3)	3 (1–7)

^a Indicates that the datum is reported as the mean with the range in parentheses

Back to article page